Biomarkers of Synaptic Damage in Multiple Sclerosis
Key facts
- Where
- Pozzilli, ItalySee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Where in Italy
- IRCCS NeuromedPozzilli, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Neuromed IRCCS
- Trial code
- NCT03217396
- Record updated
- 28 October 2022
- Original description
A prospective and retrospective cohort study of about five years will be performed on blood and cerebrospinal fluid samples taken for diagnostic reasons from recruited patients within the Neuromed Neurology Unit. Subjects with other chronic neurodegenerative diseases such as Amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD) and Parkinson's disease (PD), and healthy subjects subjected to blood sampling and / or lumbar puncture for clinical reasons will be recruited As control groups.Read full original descriptionShow less
Identification of New Biomarkers Useful to Define the Course of Multiple Sclerosis and Study of the Mechanisms That Promote Synaptic Damage
A prospective and retrospective cohort study of about five years will be performed on blood and cerebrospinal fluid samples taken for diagnostic reasons from recruited patients within the Neuromed Neurology Unit. Subjects with other chronic neurodegenerative diseases such as Amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD) and Parkinson's disease (PD), and healthy subjects subjected to blood sampling and / or lumbar puncture for clinical reasons will be recruited As control groups.
Inclusion: Male and female patients (age between 18 and 65 years); Diagnosis of MS in accordance with McDonald's (2010 rev) criteria,; EDSS between 0 and 5.5 (included),; Patients able to provide informed consent to participation in the study.
Exclusion: Significant clinical conditions in addition to SM or other chronic neurodegenerative diseases including latent viral infections; Altered basal blood count; Inability to provide informed written consent; Pregnancy or lactation; Contraindications for the execution of magnetic resonance imaging with gadolinium.